Кристи Фанк - Грудь. Руководство пользователя [litres]

J. Cuzick et al., “Selective Oestrogen Receptor Modulators in Prevention of Breast Cancer: An Updated Meta-analysis of Individual Participant Data,” The Lancet 381, no. 9880 (2013): 1827–1834.

R. T. Chlebowski et al., “Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women,” Journal of Clinical Oncology 28, no. 22 (2010): 3582–3590.

G. Rennert, M. Pinchev, and H. S. Rennert, “Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer,” Journal of Clinical Oncology 28, no. 22 (2010): 3577–3581.

T. J. Hall and M. Schaueblin, “A Pharmacological Assessment of the Mammalian Osteoclast Vacuolar H+-ATPase,” Bone and Mineral 27, no. 2 (1994): 159–166.

M. Bodmer et al., “Long-Term Metformin Use Is Associated with Decreased Risk of Breast Cancer,” Diabetes Care 33, no. 6 (2010): 1304–1308.

R. Govindarajan et al., “Thiazolidinediones and the Risk of Lung, Prostate, and Colon Cancer in Patients with Diabetes,” Journal of Clinical Oncology 25, no. 12 (2007): 1476–1481.

F. Frasca et al., “The Role of Insulin Receptors and IGF-I Receptors in Cancer and Other Diseases,” Archives of Physiology and Biochemistry 114, no. 1 (2008): 23–37; L. L. Lipscombe et al., “The Impact of Diabetes on Survival Following Breast Cancer,” Breast Cancer Research and Treatment 109, no. 2 (2008): 389–395.

A. DeCensi et al., “Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis,” Cancer Prevention Research 3, no. 11 (2010): 1451–1461.

N. D. Barnard et al., “A Low-Fat Vegan Diet Improves Glycemic Control and Cardiovascular Risk Factors in a Randomized Clinical Trial in Individuals with Type 2 Diabetes,” Diabetes Care 29, no. 8 (2006): 1777–1783.

M. F. Arisi et al., “All Trans-retinoic Acid (ATRA) Induces Re-differentiation of Early Transformed Breast Epithelial Cells,” International Journal of Oncology 44, no. 6 (2014): 1831–1842.

U. Veronesi et al., “Fifteen-Year Results of a Randomized Phase III Trial of Fenretinide to Prevent Second Breast Cancer,” Annals of Oncology 17, no. 7 (2006): 1065–1071.

E. Garattini et al., “Retinoids and Breast Cancer: from Basic Studies to the Clinic and Back Again,” Cancer Treatment Reviews 40, no. 6 (2014): 739–749.

R. E. Harris et al., Women’s Health Initiative, “Breast Cancer and Nonsteroidal Anti-inflammatory Drugs: Prospective Results from the Women’s Health Initiative,” Cancer Research 63, no. 18 (September 2003): 6096–6101. 25. L. Gallicchio et al., “Nonsteroidal Anti-inflammatory Drugs and the Risk of Developing Breast Cancer in a Population-Based Prospective Cohort Study in Washington County, MD,” International Journal of Cancer 121, no. 1 (July 2007): 211–215; E. Rahme et al., “Association between Frequent Use of Nonsteroidal Anti-inflammatory Drugs and Breast Cancer,” BMC Cancer 5 (2005): 159; T. M. Brasky et al., “Non-steroidal Antiinflammatory Drug (NSAID) Use and Breast Cancer Risk in the Western New York Exposures and Breast Cancer (WEB) Study,” Cancer Causes and Control 21, no. 9 (2010): 1503–1512.

K. K. Ludwig et al., “Risk Reduction and Survival Benefit of Prophylactic Surgery in BRCA Mutation Carriers, a Systematic Review,” The American Journal of Surgery 212, no. 4 (2016): 660–669.

L. Lostumbo et al., “Prophylactic Mastectomy for the Prevention of Breast Cancer,” Cochrane Database Systematic Reviews 4, no. 4 (October 2004).

J. K. Litton et al., “Earlier Age of Onset of BRCA Mutation‐Related Cancers in Subsequent Generations,” Cancer 118, no. 2 (2012): 321–325.

H. B. Nichols et al., “Declining Incidence of Contralateral Breast Cancer in the United States from 1975 to 2006,” Journal of Clinical Oncology 29, no. 12 (2011): 1564–1569.

L. Bertelsen et al., “Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women’s Environment, Cancer and Radiation Epidemiology Study,” Journal of the National Cancer Institute 100, no. 1 (2008): 32–40.

Y. Chen et al., “Epidemiology of Contralateral Breast Cancer,” Cancer Epidemiology, Biomarkers and Prevention 8 (1999): 855–861.

A. S. Reiner et al., “Hormone Receptor Status of a First Primary Breast Cancer Predicts Contralateral Breast Cancer Risk in the WECARE Study Population,” Breast Cancer Research 19, no. 1 (2017): 83.

J. Ji and K. Hemminki, “Risk for Contralateral Breast Cancers in a Population Covered by Mammography: Effects of Family History, Age at Diagnosis and Histology,” Breast Cancer and Research Treatment 105 (2007): 229–236.

K. Hemminki, J. Ji, and A. Forsti, “Risks for Familial and Contralateral Breast Cancer Interact Multiplicatively and Cause a High Risk,” Cancer Research 67 (2007): 868–870.

M. K. Graeser et al., “Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers,” Journal of Clinical Oncology 27 (2009): 5887–5892.

J. A. Largent et al., “Reproductive History and Risk of Second Primary Breast Cancer: The WECARE Study,” Cancer Epidemiology, Biomarkers and Prevention 16 (2007): 906–911.

J. A. Largent et al., “Reproductive History and Risk of Second Primary Breast Cancer: The WECARE Study,” Cancer Epidemiology, Biomarkers and Prevention 16 (2007): 911-915.

N. Druesne-Pecollo et al., “Excess Body Weight and Second Primary Cancer Risk after Breast Cancer: A Systematic Review and Meta-analysis of Prospective Studies,” Breast Cancer Research and Treatment 135 (2012): 647–654.

H. B. Nichols et al., “Declining Incidence of Contralateral Breast Cancer in the United States from 1975 to 2006,” Journal of Clinical Oncology 29, no. 12 (2011): 1564–1569.

L. Lostumbo, N. E. Carbine, and J. Wallace, “Prophylactic Mastectomy for the Prevention of Breast Cancer,” The Cochrane Library (2010).

T. Musiello, E. Bornhammar, and C. Saunders, “Breast Surgeons’ Perceptions and Attitudes towards Contralateral Prophylactic Mastectomy,” ANZ Journal of Surgery 83, nos. 7–8 (2013): 527–532.

C. E. Pesce et al., “Changing Surgical Trends in Young Patients with Early Stage Breast Cancer, 2003 to 2010: A Report from the National Cancer Data Base,” Journal of the American College of Surgeons 219, no. 1 (2014): 19–28.

K. L. Kummerow et al., “Nationwide Trends in Mastectomy for Early-Stage Breast Cancer,” JAMA Surgery 150 (2015): 9–16.

A. K. Arrington et al., “Patient and Surgeon Characteristics Associated with Increased Use of Contralateral Prophylactic Mastectomy in Patients with Breast Cancer,” Annals of Surgical Oncology 16, no. 10 (2009): 2697–2704.

U. Güth et al., “Increasing Rates of Contralateral Prophylactic Mastectomy – A Trend Made in USA?” European Journal of Surgical Oncology 38, no. 4 (2012): 296–301.

J. Gahm, M. Wickman, and Y. Brandberg, “Bilateral Prophylactic Mastectomy in Women with Inherited Risk of Breast Cancer – Prevalence of Pain and Discomfort, Impact on Sexuality, Quality of Life and Feelings of Regret Two Years after Surgery,” The Breast 19, no. 6 (2010): 462–469.

M. H. Frost et al., “Contralateral Prophylactic Mastectomy: Long-Term Consistency of Satisfaction and Adverse Effects and the Significance of Informed Decision Making, Quality of Life, and Personality Traits,” Annals of Surgical Oncology 18, no. 11 (2011): 3110.

S. M. Domchek et al., “Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality,” Journal of the American Medical Association 304, no. 9 (2010): 967–975.

C. Iavazzo, I. D. Gkegkes, and N. Vrachnis, “Primary Peritoneal Cancer in BRCA Carriers after Prophylactic Bilateral Salpingo-oophorectomy,” J ournal of the Turkish German Gynecological Association 17, no. 2 (2016): 73.

National Comprehensive Cancer Network, “Genetic/Familial High-Risk Assessment: Breast and Ovarian,” NCCN Clinical Practice Guidelines in Oncology, открыто 25 августа 2017, https://www.tri-kobe.org/nccn/guideline/gynecological/english/genetic_familial.pdf.

T. R. Rebbeck et al., “Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction after Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group,” Journal of Clinical Oncology 23, no. 31 (2005): 7804–7810.

K. Armstrong et al., “Hormone Replacement Therapy and Life Expectancy after Prophylactic Oophorectomy in Women with BRCA 1/2 Mutations: A Decision Analysis,” Journal of Clinical Oncology 22, no. 6 (2004): 1045–1054. Глава восьмая. Скрининг и обнаружение рака груди

J. P. Kösters and P. C. Gøtzsche, “Regular Self-Examination or Clinical Examination for Early Detection of Breast Cancer,” Cochrane Database of Systematic Reviews 2 (2003).

T. Roeke et al., “The Additional Cancer Yield of Clinical Breast Examination in Screening of Women at Hereditary Increased Risk of Breast Cancer: A Systematic Review,” Breast Cancer Research and Treatment 147, no. 1 (2014): 15–23.

F. D. Schwab et al., “Self-Detection and Clinical Breast Examination: Comparison of the Two “Classical” Physical Examination Methods for the Diagnosis of Breast Cancer,” The Breast 24, no. 1 (2015): 90–92.

B. L. Sprague et al., “National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from The Breast Cancer Surveillance Consortium,” Radiology 283, no. 1 (2017): 59–69.

S. Sayed et al., “Training Health Workers in Clinical Breast Examination for Early Detection of Breast Cancer in Low‐ and Middle‐Income Countries,” The Cochrane Library (2017).

B. C. R. Devi, T. S. Tang, and M. Corbex, “Reducing by Half the Percentage of Late-Stage Presentation for Breast and Cervix Cancer over 4 Years: A Pilot Study of Clinical Downstaging in Sarawak, Malaysia,” Annals of Oncology 18, no. 7 (2007): 1172–1176.